CERS - Why Blood Components-Focused Cerus Stock Is Rising Tuesday | Benzinga
Tuesday, Cerus Corporation (NASDAQ:CERS) announced topline results for the ReCePI Phase 3 trial of pathogen-reduced INTERCEPT Red Blood Cells (INTERCEPT RBCs) transfused to complex cardiac surgery patients.
The INTERCEPT Blood System for Red Blood Cells is designed to inactivate blood-borne pathogens and donor leukocytes in RBCs intended for transfusion.
The trial met its primary efficacy endpoint, demonstrating non-inferiority for INTERCEPT RBCs compared to conventional RBCs as measured by the incidence of acute kidney injury (AKI) following transfusion of study RBCs.
AKI is a sensitive transfusion efficacy indicator of ...